Specialized Bioanalytical Services 360biolabs offers a comprehensive range of bioanalytical and specialty laboratory services for clinical trials (Phase I-III), presenting opportunities to support biotech and pharmaceutical firms developing novel therapies, vaccines, and diagnostics requiring high-quality assay validation and method development.

Strategic Global Presence With laboratories in Australia, the United States, and Europe, 360biolabs can provide localized support for international clinical trials, making it an attractive partner for global pharmaceutical companies seeking compliant and efficient laboratory services across multiple regions.

Acquisition Expansion Recent acquisition by BioAgilytix enhances the company's reach and capabilities, offering a broader portfolio of services and increased credibility; this growth trajectory indicates potential for upselling advanced bioanalytical technologies and expanding partnership opportunities.

Regulatory Compliance Focus Adherence to strict global standards such as GLP, GCP, ISO17025, FDA, and EMA positions 360biolabs as a reliable partner for clients aiming to meet rigorous regulatory requirements, creating up-sell opportunities for advanced qualification and validation services.

Market Position & Growth Potential While currently in the revenue range of up to $10 million with a mid-sized team, the company's strategic partnerships, global footprint, and recent industry consolidations present opportunities to develop new revenue streams through additional services, technology upgrades, and expanded client engagement in the competitive biotech CRO landscape.